孤立与共突变DDX41突变髓系肿瘤的遗传特征与临床结局
DDX41 mutations (germline and somatic) are associated with late onset myelodysplastic syndromes/acute myeloid leukemia (MDS/AML).…
要点
- DDX41突变髓系肿瘤多呈惰性病程,部分患者可观察无需干预。
- mDDX41-AML的OS与预后良好亚型AML(t(8;21)、inv(16))相似。
- 多数患者核型正常,部分伴DDX41 p.R525H继发突变或其他致癌共突变。
核心结论
- mDDX41-MN患者常呈惰性病程,mDDX41-AML的OS与预后良好风险AML相当。
主要发现
- 32例患者中鉴定出14种不同致病性DDX41变异,9例患者携带8种意义未明DDX41变异。
- 5例(16%)患者存在第二个DDX41体细胞突变p.R525H,13例(40%)至少有一个其他基因的致癌共突变。
- 诊断时中位年龄66岁,男性占72%,91%患者核型正常。
- 2年总生存率为86%,6例(21%)MDS/AML患者造血功能相对保留,未进一步干预而观察。
- 与预后更有利亚型AML患者(t(8;21) n=27;inv(16) n=40)相比,本队列mDDX41患者OS相似。
临床怎么用
- 对DDX41突变髓系肿瘤患者,可考虑其惰性病程特征,部分造血功能稳定者可观察等待。
- mDDX41-AML的预后与良好风险AML相似,治疗决策时可参考此信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DDX41 mutations (germline and somatic) are associated with late onset myelodysplastic syndromes/acute myeloid leukemia (MDS/AML). Myeloid neoplasms (MN) with germline predisposition was identified as a distinct category in the 2016 WHO classification revision, including MN with germline DDX41 mutation. We retrospectively analyzed the molecular findings and clinical characteristics of thirty-three DDX41-mutated (mDDX41) patients at our institution. We identified 14 distinct pathogenic DDX41 variants in 32 patients and 8 DDX41 variants of unknown significance (VUS) in 9 patients. Five (16%) patients had a second DDX41 somatic mutation p.R525H and 13 (40%) had at least one additional oncogenic co-mutation in other genes. The median age at the time of diagnosis was 66 years, with male predominance (72%) and the majority of patients had normal cytogenetics (91%). Two-year overall survival (OS) was 86% and 6 (21%) MDS/AML patients with relatively preserved hematopoietic function were observed without further intervention. In comparison to AML patients with prognostically more favorable subtypes [t(8;21), n=27 and inv(16), n=40], mDDX41 patients in our cohort showed similarly favorable OS. Our study highlights that mDDX41-MN patients often have an indolent course and mDDX41-AML has comparable OS to favorable-risk AML.
引用
- Alkhateeb HB, Nanaa A, Viswanatha D, et al. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022. PMID: 34644397. doi:10.1182/bloodadvances.2021005738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。